April 28, 2022
May 28, 2022 –
The U.S. FDA has approved Kymriah® (tisagenlecleucel – Novartis) to treat relapsed or refractory follicular lymphoma in adults who have already received
April 28, 2022
April 28 –
VivjoaTM (oteseconazole capsules – Mycovia Pharmaceuticals) has received FDA approval to reduce the incidence of recurrent vulvovaginal candidiasis
April 28, 2022
April 28, 2022 –
Bristol Myers Squibb’s CamzyosTM (mavacamten) has been approved to improve functional capacity and symptoms as a treatment for symptomatic New York
April 25, 2022
April 25, 2022 –
Caplyta® (lumateperone) has received FDA approval for two new dosages strengths: 10.5mg capsules and 21mg capsules.
April 25, 2022
April 25, 2022 –
The U.S. FDA has approved Epsolay® (benzoyl peroxide, cream, 5%), from Sol-Gel Technologies, to treat inflammatory lesions of rosacea in adults.
April 25, 2022
April 25, 2022 – Veklury® (remdesivir) is now indicated to treat patients as young as 28 days and weighing at least 3kg (7 pounds) who have positive results of direct SARS-CoV-2
April 22, 2022
April 22, 2022 – Pfizer has recalled five lots of Accupril® (quinapril HCl) tablets due to the presence of a
nitrosamine identified as above the established acceptable daily intake
April 21, 2022
April 21, 2022 – Zerbaxa® (ceftolozane/tazobactam) has received an expanded indication to treat complicated intra-abdominal infections and complicated urinary tract infections